Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Blood Cancer: A Study of APTO-253 in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrom (MDS)

Research Question:
What is the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being?

Basic Study Information

Purpose:
This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

Location: University of Rochester Medical Center
Study Reference #: ILEU18011

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Return to Search